tbuckley/cabot-search huggingface dataset:
Tnacity: a Phase Ii/Iii Trial of Nab-Paclitaxel (Nab-P) Plus Either Gemcitabine (Gem) or Carboplatin (Carbo) Vs Gem/Carbo As First-Line Treatment for Triple-Negative Metastatic Breast Cancer (Tnmbc)
Authors: P.F. Conte, D.A. Yardley, A. Brufsky, R.E. Coleman, J. Cortes, S. Gluck, J. Nabholtz, J. O'shaughnessy, L. Li, J. Miller, D. Barton, N. Harbeck
Journal: Annals of Oncology (2014)
Measurement of lithium concentrations in human tears
Authors: R Brenner, T B Cooper, M E Yablonski, J A Lieberman, M Lesser, S G Siris, A E Rifkin
Journal: American Journal of Psychiatry (1982)

The authors compared plasma and tear lithium concentra- tions in seven outpatients receiving maintenance treatment. A strong correlationi'as found, suggesting that the mea- surement of tear lithium concentrations may be a viable alternative to plasma lithium determinations in some pa- tients. The use of blood levels as a means of monitoring drug levels is standard clinical practice for patients undergoing lithium carbonate treatment. Because the therapeutic-toxic index is rather narrow, this monitor- ing sometimes needs to be done frequently, especially in the initial phases of treatment. In some patients, however, venipunctures, especially repeated veni- punctures, may not be desirable. The disadvantages of venipunctures include the possibility of a hematoma at the venipuncture site and/or difficulty in finding a vein in some patients. In addition, blood drawing is experi- enced by some patients as physically uncomfortable, and the necessary frequency of this test procedure may lead to their diminished compliance and reluc- tance to accept lithium prophylaxis. Consequently, we evaluated the use of tears as a possible alternative body fluid for the measurement of clinical lithium concentrations. Method
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Authors: Sibylle Loibl, Silvia Darb-Esfahani, Jens Huober, Alexander Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gunter von Minckwitz, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research (2016)

Abstract Background: The PI3K/AKT pathway and phosphatase and tensin homolog (PTEN) aberrations are common in breast cancer. We investigated the correlation between phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), PTEN, p4EBP1 (phosphorylated E4 binding protein 1), and pathologic complete response (pCR) in patients receiving neoadjuvant therapy. Experimental Design: We retrospectively evaluated PIK3CA, PTEN, and p4EBP1 protein expression in centrally HER2-positive patients (n = 181) who received epirubicin cyclophosphamide/trastuzumab followed by docetaxel/trastuzumab alone or concomitant/followed by capecitabine within the GeparQuattro study. PTEN was assessed using the automated quantitative immunofluorescence analysis and was analyzed as a dichotomic variable. p4EBP1 was assessed by immunohistochemistry and used as a continuous and dichotomic variable. Results: p4EBP1 was available from 137, PTEN from 108, and PIK3CA genotype from 83 patients. Overall, the pCR rate in PTEN-low tumors was 27.6%, and in PTEN-high tumors, it was 57.1% (P = 0.010). pCR rates were not statistically different between PIK3CA wild-type and mutant (35% vs. 22%) or p4EBP1 IRS ≤ 4 and IRS &amp;gt; 4 (39% vs. 33%). pCR rate was 57.1% (8/14) in PTEN-high/PIK3CA wild-type and decreased to 15.4% in PTEN-low/PIK3CA-mutant tumors (P = 0.023). In multivariable analysis adjusted for baseline parameters, PTEN independently predicted pCR in the following cohorts: overall [OR, 7.54; 95% confidence interval (CI), 2.03–28.06; P = 0.003], PIK3CA wild-type (OR, 23.81; 95% CI, 1.75–324.05; P = 0.017), p4EBP1 IRS &amp;gt; 4 (OR, 11.53; 95% CI, 1.84–72.24; P = 0.009), and hormone receptor–positive (OR, 40.91; 95% CI, 2.93–570.44; P = 0.006). p4EBP1 was independently predictive for pCR in PIK3CA wild-type tumors (OR, 0.14; 95% CI, 0.03–0.78; P = 0.025). Conclusions: The study showed the potential role of PIK3CA genotype, PTEN, and p4EBP in predicting pCR after anthracycline–taxane-based chemotherapy and anti-HER2 treatment. Clin Cancer Res; 22(11); 2675–83. ©2016 AACR.
Safety of Viral Vaccine Cell Substrates: A Reevaluation2
Authors: John C. Petricciani, Julie B. Milstien, Adele S. Seifried, Roslyn E. Wallace, Joyce B. Johnson, Donald W. McCoy
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Safety of Viral Vaccine Cell Substrates: A Reevaluation Get access John C. Petricciani, John C. Petricciani Search for other works by this author on: Oxford Academic PubMed Google Scholar Julie B. Milstien, Julie B. Milstien Search for other works by this author on: Oxford Academic PubMed Google Scholar Adele S. Seifried, Adele S. Seifried Search for other works by this author on: Oxford Academic PubMed Google Scholar Roslyn E. Wallace, Roslyn E. Wallace Search for other works by this author on: Oxford Academic PubMed Google Scholar Joyce B. Johnson, Joyce B. Johnson Search for other works by this author on: Oxford Academic PubMed Google Scholar Donald W. McCoy Donald W. McCoy Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 4, October 1976, Pages 915–919, https://doi.org/10.1093/jnci/57.4.915 Published: 01 October 1976 Article history Received: 29 December 1975 Accepted: 24 March 1976 Published: 01 October 1976
Abstract 13035: High Plasma Levels of Endothelin-1 are Predictive of Future Cerebro- and Cardio-Vascular Events: a 20-Year Prospective Study
Authors: Salvatore Novo, Manfredi Rizzo, Angela Sansone, Fabiana Castellano, Dario Mancuso, Rosanna Iacona, Claudio Pernice, Antonino Mignano, Giuseppina Novo
Journal: Circulation (2012)

Background and purpose : Clinical and experimental evidence suggests that Endothelin-1 (Et-1) plays a crucial role in cardiac and vascular pathology. In the present study we investigated the prognostic significance of Et-1 for cerebro- and cardio-vascular outcome, in a follow-up of 20 years.   Methods : We studied 94 originally health subjects, referred to our Unit of Cardiovascular Prevention to evaluate the presence of asymptomatic carotid lesions. We subdivided these subjects into two groups, according to the plasma values of Et-1. Traditional cardiovascular risk factors were investigated, and by carotid ultrasound examination we distinguished between normal subjects and those with intima-media thickness or asymptomatic carotid plaque.   Results : Fatal or non-fatal events were registered in 41 subjects and significantly more in those with high (n=72) vs. low (n=22) Et-1 levels: 81% vs. 20%, p   Conclusions : Beyond traditional cardiovascular risk factors, plasma Et-1 levels significantly influenced cerebro- and cardio-vascular mortality.
Effect of changes in labeling and reimbursement on use of ESAs and transfusions
Authors: G. Hess, R. J. Nordyke, M. Pirolli, S. Hulnick, A. Curry, D. Gesme
Journal: Journal of Clinical Oncology (2008)

20589 Background: It has been hypothesized that recent events including a “black box” warning, recommendations from the Oncology Drugs Advisory Committee (ODAC), and changes in the CMS National Coverage Decision (NCD) may lead to reductions in the utilization of erythropoetin stimulating agents (ESAs) for chemotherapy-induced anemia (CIA), and concomitant increases in transfusions. We analyzed ESA and transfusion rates from 7 practice’s oncology electronic medical records (EMRs) pre and post the NCD to see if such a relationship was observed. Methods: A retrospective analysis compared the percent of CIA patients receiving ESAs vs. the percent receiving blood transfusions pre and post NCD. The dataset comprised 7 practices using Varian EMRs covering seven states, and providing care to 34,450 cancer patients by 194 physicians. The label change and NCD revision was in 3/07, and ODAC met 5/07 regarding ESAs. The post study period was subsequently 6/07–10/07 (post NCD) vs. a matched period 6/06–10/06 (pre NCD). The same calendar months were used to address potential seasonal influences on study outcomes. All patients were included as the NCD influences commercial insurer’s policies. Episodes of chemotherapy care (EOCC) were constructed using a 90 day gap in administration to identify the start and end of the episode, and were required to end during the pre or the post NCD period. The percent of EOCCs with myelosuppressive therapy was also assessed. The chi-square test of independence was used to assess statistical significance of the percent differences pre and post NCD. Results: The pre and post NCD study periods encompassed a total of 5,128 EOCCs: 2,323 in the pre period and 2,805 in the post period. Conclusion: Recent changes in the label, NCD and ODAC recommendations appear to be associated with a subsequent reduction in the utilization of ESAs for CIA, and a concomitant increase in patient transfusions. Further research is required to determine if this is a persistent and generalizable change in practice patterns. ESAs and Transfusions in Patients Receiving Chemotherapy EOCCs with: Pre NCD % Post NCD % Chi-Square Myelosuppressive Chemotherapy 30.7% 29.4% P = 0.3137 ESA Administrations 40.0% 32.9% P < 0.0001 Blood Transfusions 6.5% 8.9% P = 0.0013 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Inc. Amgen Inc. Amgen Inc.
453P Development of skin rash within the first week is a potential surrogate marker of effect in afatinib for EGFR mutant NSCLC: Okayama Lung Cancer Study Group Experience
Authors: A. Bessho, S. Hosokawa, K. Hotta, K. Kudo, N. Nogami, S. Kuyama, K. Gemba, K. Inoue, T. Okada, N. Takigawa, M. Tanimoto, K. Kiura
Journal: Annals of Oncology (2015)
Lesson of the week: Carotid dissection causing stroke in a child with migraine
Authors: V Ganesan, F J Kirkham
Journal: BMJ (1997)

Reduction of the calcium ion content of the fluid surrounding the rectus abdominis muscle of the frog greatly sensitizes the response of this muscle to stimulation by potassium ions. The response to acetylcholine is also potentiated, but not to the same degree. The addition of guanidine or veratrine to the fluid bathing the muscle causes a similar change in the reaction evoked by potassium ions, and the effects of both of these drugs can be counteracted by calcium ions. These factors must be considered in the analysis of the alterations in excitability and activity of both muscle and nerve fibres in pathological states such as parathyroid tetany, and in those resulting from the action of certain drugs.
A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data
Authors: N.H. Segal, O. Hamid, W. Hwu, C. Massard, M. Butler, S. Antonia, A. Blake-Haskins, P.B. Robbins, X. Li, J. Vasselli, S. Khleif
Journal: Annals of Oncology (2014)
Framingham risk score after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer: A controlled observational study
Authors: T. M. Michelsen, S. Tonstad, A. A. Dahl, A. H. Pripp, C. G. Tropé, A. Dørum
Journal: Journal of Clinical Oncology (2009)

11048 Background: Risk-reducing salpingo-oophorectomy (RRSO) effectively prevents ovarian cancer in BRCA mutation carriers and in women at risk for hereditary breast-ovarian cancer. RRSO induces immediate menopause, which may increase the risk of coronary heart disease (CHD). Our aim was to determine CHD risk using Framingham risk score and examine factors associated with this risk in women who had undergone RRSO compared to population-based controls. Methods: A sample of 326 (65% of invited) women who underwent RRSO after genetic counseling from 1980–2005 provided completed questionnaires, physical measures, and blood samples. Controls were 1,630 age-matched controls from the Norwegian Nord-Trøndelag Health Study (HUNT-2) (1995- 97). Results: Mean age in both the RRSO and control groups at survey was 54.4 years. Mean follow-up after surgery was 6.5 years (SD 4.4). The RRSO group had a more favorable CHD risk profile (higher education, more physical activity, less smoking, lower total cholesterol, higher HDL cholesterol, lower systolic blood pressure and lower BMI) and lower Framingham total score compared to controls (p&lt;0.05). In multiple logistic regression analyses RRSO was inversely associated with Framingham 10-year risk ≥5% (Odds Ratio 0.49, 95% CI [0.34, 0.71] p&lt;0.001). Conclusions: In contrast to expectation, women at increased risk of hereditary breast ovarian cancer had a favorable CHD risk profile after RRSO compared to age-matched controls from the general population, and RRSO was associated with lower Framingham risk score. Follow-up time, self-selection of women seeking genetic counseling, changes in lifestyle after surgery and survival bias are possible explanations of this finding. No significant financial relationships to disclose.
Interval from neoadjuvant chemotherapy to interval debulking surgery in advanced ovarian cancer: Is this a prognostic indicator?
Authors: R. Hariprasad, L. Kumar, A. Mookerjee, V. Radhakrishnan, S. Kumar, S. Mathur, S. Thulkar
Journal: Journal of Clinical Oncology (2010)

5084 Background: We hypothesized that longer interval between neoadjuvant chemotherapy and interval debulking surgery (IDS) may have an adverse effect on survival. We analyzed the data of patients with advanced epithelial ovarian cancer to evaluate the effect of interval from last cycle of chemotherapy to interval debulking surgery (IDS) on progression free and overall survival. Methods: We retrospectively analyzed case records of 86 patients of advanced epithelial ovarian cancer (stage IIIC and IV) who received neoadjuvant chemotherapy and underwent IDS at our centre from Jan 2001 to Dec 2008. Data was obtained for age, stage of the disease, operative procedure, pathology, recurrence and survival. Response rate was compared using 2 sided chi square test. Progression free (PFS) and overall survival (OS) were analyzed using Kaplan Meier technique with log rank test. Hazard ratio was obtained by cox regression model. Results: Patients' median age was 50 years (range 32 to 75). 55 patients had stage IIIC and stage IV-31. A median of 3 chemotherapy cycles were administered prior to IDS (range, 3-7) and the median interval between last cycle of chemotherapy and IDS was 41 days (range 16-93 days). 67.5% patients had optimal debulking (residual disease ≤ 1 cm). 44 patients were operated within 42 days and 42 patients underwent surgery after 42 days. The response rate (complete + partial) was higher for patients operated within 42 days (40/44 vs. 30/42, p < 0.02). At a median follow up of 30 months- the median overall and PFS for whole group is 37 months (95% CI: 30-44) and 13 months (95% CI: 11-15), respectively. Both PFS and OS rates are significantly higher for patients operated within 42 days of last chemotherapy cycle; PFS: 18 vs. 9 months, p < 0.0001, HR-2.86 (95% CI:1.76-4.67) and OS: 45 vs. 27 months, p < 0.003, HR-2.19 (95% CI:1.27-3.79). Conclusions: This study indicates adverse outcome for patients who undergo interval debulking surgery more than 6 weeks after last cycle of neoadjuvant chemotherapy. No significant financial relationships to disclose.
NDM-1- or OXA-48-producing Enterobacteriaceae colonising Polish tourists following a terrorist attack in Tunis, March 2015
Authors: R Izdebski, K Bojarska, A Baraniak, E Literacka, M Herda, D Żabicka, A Guzek, M Półgrabia, W Hryniewicz, M Gniadkowski
Journal: Eurosurveillance (2015)

We describe the introduction of NDM-1-producing Klebsiella pneumoniae ST147 and Escherichia coli ST410, and OXA-48-producing K. pneumoniae ST101 strains to Poland by two patients transported to the country after hospitalisation in Tunisia. The patients had gunshot wounds following the terrorist attack in the Bardo National Museum in Tunis in March 2015. Our report reinforces the need for microbiological screening of patients returning from travel on admission to healthcare institutions, especially following hospitalisation in countries where carbapenemase-producing Enterobacteriaceae are endemic.
Modeling Smith-Lemli-Opitz syndrome with induced pluripotent stem cells reveals a causal role for Wnt/β-catenin defects in neuronal cholesterol synthesis phenotypes
Authors: Kevin R Francis, Amy N Ton, Yao Xin, Peter E O'Halloran, Christopher A Wassif, Nasir Malik, Ian M Williams, Celine V Cluzeau, Niraj S Trivedi, William J Pavan, Wonhwa Cho, Heiner Westphal, Forbes D Porter
Journal: Nature Medicine (2016)
Abstract 18840: Left Ventricular Enlargement Detected by Cardiac Magnetic Resonance Imaging Predicts Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation
Authors: Daniel K Pu, Jonathan W Weinsaft, Frank S Lin, Jake M Chanin, James E Ip, Steven M Markowitz, Christopher F Liu, George Thomas, Bruce B Lerman, Jim W Cheung
Journal: Circulation (2014)

Introduction: Recurrence rates of atrial fibrillation (AF) following catheter ablation remain substantial. Studies on cardiac magnetic resonance imaging (cMRI) assessment of predictors of AF recurrence following pulmonary vein (PV) isolation have centered on left atrial volume and fibrosis. We sought to identify other anatomic predictors of recurrent AF following PV isolation by cMRI. Methods: Eighty-seven consecutive patients (72 [83%] male; age 61 ± 10 yrs) who underwent PV isolation for symptomatic AF (63% paroxysmal) and baseline cMRI were evaluated. Baseline left ventricular (LV) mass, LV end-diastolic and end-systolic volumes, LV size, LV ejection fraction, left atrial diameter and area, right atrial sizes, right ventricular size and function and presence of left common PV and right middle PV were assessed by cMRI. Recurrent AF (defined as AT/AF ≥ 30 seconds) during follow up was noted. Results: Over mean follow-up of 372 ± 109 days, a total of 30 (35%) patients had evidence of recurrent AF. Patients with LV enlargement (≥ mild) by cMRI had significantly reduced AF-free survival (53% vs. 73% at 1 year; p = 0.012) and patients with LV mass index ≥ 74.5 g/m 2 had significantly reduced AF-free survival (54% vs. 72% at 1 year; p = 0.031). There was no difference in AF-free survival among patients with and without left atrial, right atrial, and right ventricular enlargement. Patients with and without recurrent AF had similar right ventricular function and LV ejection fractions. In a multivariate analysis of cMRI parameters of cardiac anatomy, LV enlargement was the only significant independent predictor of recurrent AF (HR 2.78; 95% CI 1.26-6.11; p=0.011). Conclusion: Left ventricular enlargement assessed by cMRI is a significant independent predictor of recurrent AF following PV isolation. In addition to abnormal left atrial substrate, negative LV remodeling may also be an important marker of increased susceptibility to AF after ablation.
Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the National Cancer Institute of Milan
Authors: M Colleoni, E Bajetta, P Nelli, L Boni, A M Bochicchio, F Nolè, R Buzzoni, L Celio, V Mazzaferro, G Bonfanti
Journal: Annals of Oncology (1993)
The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells
Authors: I Matsumura, Y Kanakura, T Kato, H Ikeda, Y Horikawa, J Ishikawa, H Kitayama, T Nishiura, Y Tomiyama, H Miyazaki, Y Matsuzawa
Journal: Blood (1996)
NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143)
Authors: Antonio Omuro, Joachim Baehring, Solmaz Sahebjam, Gordana Vlahovic, Alfredo Voloschin, Robert Young, Wendy Hayes, Robert Latek, Vlad Coric, Timothy Cloughesy, Michael Lim, John Sampson, David A. Reardon
Journal: Neuro-Oncology (2015)

BACKGROUND: Determining disease progression and response in glioblastoma (GBM) is challenging as standard therapies may alter tumor enhancement on MRI and technical factors complicate interpretation of imaging results in multicenter trials. The emergence of investigational immunomodulatory agents for GBM has further challenged investigators to distinguish possible treatment-related immunologic reactions at the tumor site from disease progression using non-invasive imaging techniques. METHODS: Eligible patients had first recurrence of primary GBM, no prior bevacizumab treatment, and KPS ≥70. Patients were randomized to nivolumab 3 mg/kg Q2W (NIVO) or nivolumab 1 mg/kg + ipilimumab 3 mg/kg Q3W followed by nivolumab 3 mg/kg Q2W (NIVO + IPI). Participating institutions underwent imaging standardization; sites were qualified and images were read locally then transmitted to an independent imaging core lab. MRI was obtained at baseline, week 7, week 13, then Q8W. RANO criteria were applied. Select patients (n = 7) underwent advanced and exploratory neuroimaging, including dynamic contrast-enhanced MRI (DCE-MRI) and [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET). RESULTS: Twenty patients were enrolled (NIVO, n = 10; NIVO + IPI, n = 10). Median age: 57 (range 37–73); MGMT: methylated (n = 4), unmethylated (n = 10), and undetermined (n = 6). Investigator-assessed objective responses: partial response (n = 1), stable disease (n = 8), and progression (n = 10). A subset of patients demonstrated biopsy-confirmed immune-related treatment effects, with pathology showing reactive changes and minimal to no tumor. Additional neuroimaging in one of these patients showed hypermetabolism on the FDG-PET scan, while the DCE-MRI results were equivocal, with only mildly increased Ktrans and plasma volume. Standard and advanced neuroimaging results from this preliminary cohort will be reported. CONCLUSIONS: Use of checkpoint inhibitors in GBM may be associated with treatment-related imaging changes that may be difficult to distinguish from disease progression using standard MRI imaging. Additional multi-modality imaging studies, particularly perfusion MRI, may be helpful to address such discordant findings.